Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Prior treatment

• Had previously received therapy targeting immune modulatory receptors or related pathways (including but not limited to therapy targeting PD-1, CTLA-4, IDO, PD-L1, LAG-3, TIGIT, IL-2R and GITR, etc, but excluding related cytokine therapy such as IL2), excluding patients who had received immunotherapy such as anti-PD- (L) 1 antibody in adjuvant/neoadjuvant therapy setting and did not progress within 6 months after discontinuation;
• Receiving approved systemic anti-tumor therapy within 2 weeks prior to the first dose;
• Toxicities caused by prior anti-tumor therapy before the first dose that did not recover to Grade 0 or 1 per the NCI CTCAE v5.0 or to the level specified in the enrollment criteria (excluding alopecia and peripheral neurotoxicity ≤ CTCAE Grade 2);
• Immunosuppression medication within 4 weeks prior to randomization;
• Toxicities caused by prior anti-tumor therapy before the first dose that did not recover to Grade 0 or 1 per the National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) v5.0 or to the level specified in the enrollment criteria (excluding alopecia and peripheral neurotoxicities ≤CTCAE Grade 2 caused by platinum-based chemotherapy; thyroid dysfunction with stable disease control after symptomatic treatment);
• Patient with evidence or history of haemorrhagic tendency within 2 months prior to the first dose, regardless of severity.

Other illness

• Patients with active autoimmune or inflammatory diseases;
• History of pneumonitis requiring corticosteroid therapy, or history of or current interstitial lung disease, or current active pulmonary infection, etc.;
• Human Immunodeficiency Virus (HIV) Infection (HIV 1/2 Antibody positive);
• Uncontrolled hypertension despite standard therapy;

Other

• Known central nervous system (CNS) metastasis;

• 18 to 75 (inclusive) years of age on the date when ICF was signed;
• Histologically or cytologically confirmed renal clear cell carcinoma;
• Patients with locally advanced/metastatic renal carcinoma;
• Patients with renal carcinoma who progressed during or after or intolerant to previous first-line VEGFR-TKI therapy for advanced/metastatic disease;
• At least 1 measurable lesion according to RECIST 1.1;
• ECOG PS of 0 or 1;
• Adequate organ function.